VF1
MCID: VNT034
MIFTS: 67

Ventricular Fibrillation, Paroxysmal Familial, 1 (VF1)

Categories: Genetic diseases, Rare diseases

Aliases & Classifications for Ventricular Fibrillation, Paroxysmal Familial, 1

MalaCards integrated aliases for Ventricular Fibrillation, Paroxysmal Familial, 1:

Name: Ventricular Fibrillation, Paroxysmal Familial, 1 56 73
Ventricular Fibrillation 43 17 71
Paroxysmal Familial Ventricular Fibrillation 1 29 6
Ventricular Fibrillation, Familial, 1 56 13
Vf1 56 73
Ivf 56 73
Vf 56 73
Susceptibility to Ventricular Fibrillation During Myocardial Infarction 73
Fibrillation, Ventricular, Paroxysmal, Familial, Type 1 39
Familial Paroxysmal Ventricular Fibrillation 1 73
Ventricular Fibrillation Adverse Event 71
Fibrillation, Ventricular 39

Classifications:



External Ids:

OMIM 56 603829
MeSH 43 D014693
MedGen 41 C2751898
UMLS 71 C0042510 C1962976

Summaries for Ventricular Fibrillation, Paroxysmal Familial, 1

OMIM : 56 Ventricular fibrillation (VF) is said to cause more than 300,000 sudden deaths each year in the US alone. In approximately 5 to 12% of cases, there are no demonstrable cardiac or noncardiac causes to account for the episode, which is therefore classified as idiopathic ventricular fibrillation (IVF). Patients with a distinct form of VF called Brugada syndrome (see 601144) present with a characteristic electrocardiographic pattern, with right bundle branch block (RBBB) and elevation of ST segment in leads V1 to V3 and may account for 40 to 60% of all IVF cases (review by Chen et al., 1998). Mutations in the SCN5A gene were identified in patients with Brugada syndrome-1 (601144). (603829)

MalaCards based summary : Ventricular Fibrillation, Paroxysmal Familial, 1, also known as ventricular fibrillation, is related to ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy and right bundle branch block, and has symptoms including chest pain An important gene associated with Ventricular Fibrillation, Paroxysmal Familial, 1 is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are DAG and IP3 signaling and Cardiac conduction. The drugs Empagliflozin and Metoprolol have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are syncope and tachycardia

UniProtKB/Swiss-Prot : 73 Familial paroxysmal ventricular fibrillation 1: A cardiac arrhythmia marked by fibrillary contractions of the ventricular muscle due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricle and by absence of atrial activity.

Wikipedia : 74 Ventricular fibrillation (V-fib or VF) is an abnormal heart rhythm in which the ventricles of the heart... more...

Related Diseases for Ventricular Fibrillation, Paroxysmal Familial, 1

Diseases in the Paroxysmal Ventricular Fibrillation family:

Ventricular Fibrillation, Paroxysmal Familial, 1 Ventricular Fibrillation, Paroxysmal Familial, 2

Diseases related to Ventricular Fibrillation, Paroxysmal Familial, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 634)
# Related Disease Score Top Affiliating Genes
1 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 33.0 SCN5A RYR2 KCNQ1 KCNH2 DSP
2 right bundle branch block 31.1 SCN5A KCNH2 CACNA1C
3 hypokalemia 30.9 KCNQ1 KCNJ5 KCNH2
4 cardiac arrhythmia, ankyrin-b-related 30.9 SCN5A RYR2 KCNQ1 KCNJ5 KCNH2 KCNE2
5 atrial standstill 1 30.8 TNNT2 SCN5A RYR2 DSP
6 wolff-parkinson-white syndrome 30.7 TNNT2 SCN5A RYR2 NKX2-5 KCNQ1 KCNH2
7 sick sinus syndrome 30.6 SCN5A KCNQ1 CACNA1C
8 left bundle branch hemiblock 30.5 TNNT2 SCN5A RYR2 DSP
9 brugada syndrome 1 30.4 SCN5A RYR2 KCNH2
10 cardiac conduction defect 30.1 SCN5A RYR2 KCNQ1 KCNH2 DSP
11 sudden infant death syndrome 30.1 SCN5A RYR2 KCNQ1 KCNH2
12 familial short qt syndrome 30.1 KCNQ1 KCNH2
13 long qt syndrome 1 30.1 TNNT2 SCN5A RYR2 NKX2-5 KCNQ1 KCNJ5
14 hypokalemic periodic paralysis, type 1 30.0 SCN5A KCNE1 CACNA1C
15 atrial heart septal defect 29.9 TNNT2 SCN5A NKX2-5
16 ebstein anomaly 29.8 TNNT2 SCN5A NKX2-5
17 arrhythmogenic right ventricular cardiomyopathy 29.8 SCN5A RYR2 KCNH2 KCNE1 DSP CACNA1C
18 restrictive cardiomyopathy 29.7 TNNT2 DSP CACNA1C
19 brugada syndrome 4 29.6 SCN5A KCNQ1 KCNH2 CACNA1C
20 tetralogy of fallot 29.6 TNNT2 SCN5A NKX2-5 KCNH2
21 cardiac arrest 29.5 TNNT2 SCN5A RYR2 KNG1 KCNQ1 KCNH2
22 syncope 29.5 TNNT2 SCN5A RYR2 KCNQ1 KCNH2
23 familial long qt syndrome 29.5 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 CACNA1C
24 cardiac arrhythmia 29.4 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 CACNA1C
25 atrioventricular block 29.2 SCN5A RYR2 NKX2-5 KCNQ1 KCNH2 KCNE2
26 congestive heart failure 29.2 TNNT2 SCN5A RYR2 KNG1 KCNQ1 KCNE2
27 myocardial stunning 29.2 TNNT2 SLC9A1 KNG1 KCNJ5
28 long qt syndrome 14 29.1 SCN5A KCNQ1 KCNH2 KCNE1 CACNA1C
29 long qt syndrome 29.0 SCN5A RYR2 KCNQ1 KCNJ5 KCNH2 KCNE2
30 jervell and lange-nielsen syndrome 1 28.9 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 CACNA1C
31 migraine with or without aura 1 28.9 SCN5A NGF KNG1 CACNA1C
32 short qt syndrome 28.8 SCN5A RYR2 KCNQ1 KCNJ5 KCNH2 KCNE2
33 atrial fibrillation 28.6 TNNT2 SCN5A RYR2 KCNQ1 KCNJ5 KCNH2
34 long qt syndrome 3 28.5 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 KCNE1
35 timothy syndrome 28.4 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 KCNE1
36 lipoprotein quantitative trait locus 28.4 TNNT2 SCN5A RYR2 NKX2-5 KNG1 KCNJ5
37 hypertension, essential 28.3 TNNT2 SLC9A1 RYR2 KNG1 KCNJ5 CACNA1C
38 andersen cardiodysrhythmic periodic paralysis 28.0 SCN5A RYR2 KCNQ1 KCNJ5 KCNH2 KCNE2
39 left ventricular noncompaction 28.0 TNNT2 SCN5A RYR2 NKX2-5 KCNQ1 KCNH2
40 catecholaminergic polymorphic ventricular tachycardia 28.0 TNNT2 SCN5A RYR2 KCNQ1 KCNJ5 KCNH2
41 hypertrophic cardiomyopathy 28.0 TNNT2 SCN5A RYR2 NKX2-5 KCNQ1 KCNJ5
42 brugada syndrome 27.7 TNNT2 SCN5A RYR2 NKX2-5 KCNQ1 KCNJ5
43 heart disease 27.1 TNNT2 SCN5A RYR2 NKX2-5 KNG1 KCNQ1
44 dilated cardiomyopathy 26.8 TNNT2 SCN5A RYR2 NKX2-5 KNG1 KCNQ1
45 ventricular fibrillation, paroxysmal familial, 2 12.8
46 early repolarization associated with ventricular fibrillation 12.8
47 idiopathic ventricular fibrillation, non brugada type 12.6
48 premature ovarian failure 1 11.7
49 polycystic ovary syndrome 11.7
50 ventricular tachycardia, familial 11.6

Comorbidity relations with Ventricular Fibrillation, Paroxysmal Familial, 1 via Phenotypic Disease Network (PDN): (show all 19)


Acute Cystitis Acute Kidney Failure
Aortic Valve Disease 1 Cardiac Arrest
Cardiogenic Shock Deficiency Anemia
Dressler's Syndrome Familial Atrial Fibrillation
First-Degree Atrioventricular Block Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Mitral Valve Disease Ocular Motor Apraxia
Peripheral Vascular Disease Respiratory Failure
Sinoatrial Node Disease Third-Degree Atrioventricular Block
Tricuspid Valve Disease

Graphical network of the top 20 diseases related to Ventricular Fibrillation, Paroxysmal Familial, 1:



Diseases related to Ventricular Fibrillation, Paroxysmal Familial, 1

Symptoms & Phenotypes for Ventricular Fibrillation, Paroxysmal Familial, 1

Human phenotypes related to Ventricular Fibrillation, Paroxysmal Familial, 1:

31
# Description HPO Frequency HPO Source Accession
1 syncope 31 HP:0001279
2 tachycardia 31 HP:0001649
3 ventricular fibrillation 31 HP:0001663

Clinical features from OMIM:

603829

UMLS symptoms related to Ventricular Fibrillation, Paroxysmal Familial, 1:


chest pain

MGI Mouse Phenotypes related to Ventricular Fibrillation, Paroxysmal Familial, 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 CACNA1C DSP KCNH2 KCNJ5 KCNQ1 NGF
2 growth/size/body region MP:0005378 10 DSP KCNE2 KCNH2 KCNQ1 KNG1 NGF
3 homeostasis/metabolism MP:0005376 9.9 CACNA1C CHKB KCNE2 KCNH2 KCNQ1 KNG1
4 embryo MP:0005380 9.87 CACNA1C DSP KCNH2 NKX2-5 RYR2 SCN5A
5 muscle MP:0005369 9.65 CACNA1C CHKB DSP KCNH2 KCNQ1 NGF
6 nervous system MP:0003631 9.32 CACNA1C CHKB DSP KCNQ1 NGF NKX2-5

Drugs & Therapeutics for Ventricular Fibrillation, Paroxysmal Familial, 1

Drugs for Ventricular Fibrillation, Paroxysmal Familial, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 220)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Empagliflozin Approved Phase 4 864070-44-0
2
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
3
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
6
Metolazone Approved Phase 4 17560-51-9 4170
7
Tolvaptan Approved Phase 4 150683-30-0 216237
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
10
Prilocaine Approved Phase 4 721-50-6 4906
11
Atorvastatin Approved Phase 4 134523-00-5 60823
12 Grape Approved Phase 4
13
Cangrelor Approved Phase 4 163706-06-7 9854012
14
Ticagrelor Approved Phase 4 274693-27-5 9871419
15
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
16
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
17
Ezetimibe Approved Phase 4 163222-33-1 150311
18
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
19
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
20 Kava Approved, Investigational, Nutraceutical Phase 4 9000-38-8
21
Simendan Investigational Phase 4 131741-08-7
22 Sodium-Glucose Transporter 2 Inhibitors Phase 4
23 Hypoglycemic Agents Phase 4
24 diuretics Phase 4
25 Hormones Phase 4
26 Vasopressins Phase 4
27 Arginine Vasopressin Phase 4
28 Sodium Chloride Symporter Inhibitors Phase 4
29 Anesthetics, Local Phase 4
30 Nifekalant Phase 4
31 Ketorolac Tromethamine Phase 4
32 Cyclooxygenase Inhibitors Phase 4
33 Anti-Inflammatory Agents Phase 4
34 Anti-Inflammatory Agents, Non-Steroidal Phase 4
35 Hypolipidemic Agents Phase 4
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
37 Lipid Regulating Agents Phase 4
38 Anticholesteremic Agents Phase 4
39 Antimetabolites Phase 4
40 Cardioplegic Solutions Phase 4
41 Purinergic P2Y Receptor Antagonists Phase 4
42 Prasugrel hydrochloride Phase 4 389574-19-0
43 Plasma-lyte 148 Phase 4
44 Analgesics, Non-Narcotic Phase 4
45 Psychotropic Drugs Phase 4
46 Hypnotics and Sedatives Phase 4
47 Anesthetics, General Phase 4
48 Anti-Anxiety Agents Phase 4
49 GABA Modulators Phase 4
50 Anesthetics, Intravenous Phase 4

Interventional clinical trials:

(show top 50) (show all 310)
# Name Status NCT ID Phase Drugs
1 Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias. A Prospective, Randomized Multicentre Study. Unknown status NCT02303639 Phase 4 Antiarrhythmic drug therapy
2 "Test-No Test" Implantable Cardioverter Defibrillator Pilot Study (TNT-ICD) Unknown status NCT01905007 Phase 4
3 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
4 The Effect of Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients Unknown status NCT03271879 Phase 4 Empagliflozin at a dose of 10 mg/day
5 Cholesterol Lowering and Arrhythmia Recurrences After Internal Defibrillator Implantation (CLARIDI) Completed NCT00457340 Phase 4 Atorvastatin 80mg
6 Efficacy of Different Perioperative Statin Regimens on the Protection Against Post Coronary Artery Bypass Grafting Major Adverse Cardio-cerebral Events Completed NCT02706860 Phase 4 Atorvastatin
7 Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER) Completed NCT00101881 Phase 4
8 Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICDs Study Completed NCT00231426 Phase 4
9 ADVANCE-D: ATP Delivery for Painless ICD Therapy Completed NCT00147277 Phase 4
10 VERRARI - "Are Ventricular Arrhythmic Episodes Reduced by Rate Response in ICDs?" Completed NCT00180427 Phase 4
11 hs Troponin Release in Relation to Different ICD-Implantation Procedures Completed NCT01230086 Phase 4
12 Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
13 Clinical Interest of Endovascular Cooling in the Management of Cardiac Arrest: Impact on Mortality in a Randomized Medico-economical Trial (the ICEREA Study) Completed NCT00392639 Phase 4
14 ADVANCE CRT - D: ATP Delivery for Painless ICD Therapy Completed NCT00147290 Phase 4
15 Remote Follow-up for ICD-Therapy in Patients Meeting MADIT II Criteria (REFORM) Completed NCT00401466 Phase 4
16 IN-TIME: Influence of Home Monitoring on the Clinical Status of Heart Failure Patients Completed NCT00538356 Phase 4
17 Clopidogrel Or Metoprolol in Myocardial Infarction Trial Completed NCT00222573 Phase 4 clopidogrel and metoprolol
18 A Randomised Trial on Early Stress Nuclear Scan for Patients Presented to the Emergency Department (ED) With Chest Pain But Non-diagnostic Electrocardiography-Acute Chest Pain Treatment and Evaluation (ACTION) Study Completed NCT00434564 Phase 4
19 Reduction And Prevention of Tachyarrhythmias and Shocks Using Reduced Ventricular Pacing With Atrial Algorithms (The RAPTURE Study) Completed NCT00787800 Phase 4
20 Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan Completed NCT01221649 Phase 4
21 Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET) Completed NCT02261948 Phase 4 Levosimendan;Placebo
22 Effect of Cardiac Resynchronization Therapy (CRT) on the Defibrillation Threshold (DFT) Estimates Completed NCT00626093 Phase 4
23 Fast VT Episodes Are Terminated by ATP One Shot Completed NCT00617578 Phase 4
24 Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement Completed NCT00711360 Phase 4
25 Survival of Patients With Primary Prophylactic ICD Indication, Provided With Intensified Care After 1st ICD Therapy Completed NCT00619593 Phase 4
26 Comparison of Oral Thiazides vs Intravenous Thiazides vs Tolvaptan in Combination With Loop Diuretics for Diuretic Resistant Decompensated Heart Failure Completed NCT02606253 Phase 4 tolvaptan;Chlorothiazide;Metolazone
27 Lidocaine Versus Ketorolac for the Management of Renal Colic Recruiting NCT03137498 Phase 4 Lidocaine;Ketorolac
28 Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection in the Treatment of Ventricular Tachycardia and Ventricular Fibrillation. A Multicenter, Randomized, Controlled, Open-label, Clinical Trial. Recruiting NCT03855826 Phase 4 Nifekalant hydrochloride;Amiodarone
29 Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management Recruiting NCT03273075 Phase 4 Cangrelor;Placebo;Prasugrel;Ticagrelor
30 Clinical Outcomes of Del Nido Cardioplegia in Adult Cardiac Surgery: a Randomized Controlled Trial Recruiting NCT04094168 Phase 4 DEL NIDO CARDIOPLEGIA;COLD BLOOD BASED CARDIOPLEGIA
31 Assessment of the Effects of Long-term Lipid-lowering Therapy on Parameters of Electrical Myocardial Heterogeneity, Myocardial Deformation Characteristics, Vascular Rigidity, and Quality of Life in Patients With Primary STEMI or NSTEMI Recruiting NCT04347434 Phase 4 Atorvastatin 80mg
32 RANDOMİZED,DOUBLE-BLİND TRİAL OF EFFECT OF DEXMEDETOMİDİNE AND MİDAZOLAM SEDATİON ON HEART RATE VARİABİLİTY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY Active, not recruiting NCT03601091 Phase 4 Precedex 200 MCG in 2 ML Injection;DORMICUM 5MG/5 ML
33 CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial) Not yet recruiting NCT03826524 Phase 4 Epinephrine
34 Effect of Heart Rate Control Using Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Ventricular Pacing in Heart Failure Patients With an Implanted Cardioverter Defibrillator. Withdrawn NCT01868880 Phase 4 Ivabradine plus beta-blocker (bisoprolol);betablocker titration
35 A Multicentre Prospective Randomised Study Comparing the Efficacy of High Versus Low Biphasic Energy Defibrillation in Patients With Cardiac Arrest Unknown status NCT00429611 Phase 3
36 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
37 CONTAK RENEWAL 4 AVT Field Following Completed NCT00180336 Phase 2, Phase 3
38 Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT) Completed NCT01401647 Phase 3 amiodarone;Lidocaine
39 Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed NCT00000464 Phase 3 amiodarone;imipramine;mexiletine;procainamide;propafenone;quinidine;sotalol
40 Impact of Hyperoxia During Cardiopulmonary Bypass in the Occurrence of Cardiovascular Complications After Cardiac Surgery Completed NCT02819739 Phase 3 medical oxygen
41 Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Completed NCT00000518 Phase 3 imipramine;mexiletine;procainamide;quinidine;sotalol
42 VENTAK CHF/CONTAK CD Biventricular Pacing Study Completed NCT00387803 Phase 2, Phase 3
43 Fatty Acid Antiarrhythmia Trial (FAAT) Completed NCT00004559 Phase 3
44 A Pilot Randomized Controlled Trial to Compare Fixed Versus Escalating Energy Regimens for Biphasic Waveform Defibrillation Completed NCT00212992 Phase 3
45 Antiarrhythmics Versus Implantable Defibrillators (AVID) Completed NCT00000531 Phase 3 amiodarone amiodarone;sotalol
46 Coronary Surgery: Comparing the Protective Effects of Two Cardioplegic Solutions: Custodiol Versus St Thomas, on Cardiac Metabolism, as Assessed Using Microdialysis Completed NCT01401140 Phase 3 St Thomas;Custodiol
47 Evaluation of the Interests of a Therapeutic Hypothermia Procedure in Convulsive Status EPILEPTICUS in Adults in Intensive Care - HYBERNATUS Study Completed NCT01359332 Phase 3
48 Evaluation of SC-V Versus Conventional CPR Completed NCT00000502 Phase 3
49 Randomized Controlled Pilot Study: Induction of Mild Hypothermia in Resuscitated Cardiac Arrest Patients Using Traditional Surface Cooling Techniques vs. the Medivance® Arctic Sun® System Completed NCT00282373 Phase 2, Phase 3
50 Late Sodium Current Blockade in High-Risk ICD Patients Completed NCT01215253 Phase 3 Ranolazine

Search NIH Clinical Center for Ventricular Fibrillation, Paroxysmal Familial, 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acebutolol
Acebutolol Hydrochloride
Amiodarone
Amiodarone hydrochloride
Atenolol
bretylium
Bretylium Tosylate
Edetic Acid, Disodium Salt
Epinephrine
epinephrine bitartrate
epinephrine hydrochloride
epinephryl borate
esmolol
Esmolol hydrochloride
Isoproterenol
Isoproterenol Hydrochloride
Isoproterenol Sulfate
Lidocaine
LIDOCAINE HCL PWDR
Lidocaine Hydrochloride
LIDOCAINE PWDR
Magnesium Sulfate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Mexiletine
Mexiletine Hydrochloride
Moricizine
Moricizine hydrochloride
Propranolol
Propranolol Hydrochloride
Racepinephrine Hydrochloride
Sotalol
Sotalol Hydrochloride
Vasopressin (USP)
VASOPRESSIN TANNATE (IN OIL)

Cochrane evidence based reviews: ventricular fibrillation

Genetic Tests for Ventricular Fibrillation, Paroxysmal Familial, 1

Genetic tests related to Ventricular Fibrillation, Paroxysmal Familial, 1:

# Genetic test Affiliating Genes
1 Paroxysmal Familial Ventricular Fibrillation 1 29 SCN5A

Anatomical Context for Ventricular Fibrillation, Paroxysmal Familial, 1

MalaCards organs/tissues related to Ventricular Fibrillation, Paroxysmal Familial, 1:

40
Heart, Testes, Brain, Lung, Liver, Thyroid, Kidney

Publications for Ventricular Fibrillation, Paroxysmal Familial, 1

Articles related to Ventricular Fibrillation, Paroxysmal Familial, 1:

(show top 50) (show all 17684)
# Title Authors PMID Year
1
A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome. 6 56 61
10940383 2000
2
Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. 61 56
20622880 2010
3
Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. 56 61
9521325 1998
4
Mode of onset of malignant ventricular arrhythmias in idiopathic ventricular fibrillation. 61 56
9363814 1997
5
Idiopathic ventricular fibrillation. 61 56
2202193 1990
6
Paroxysmal familial ventricular fibrillation. 61 56
4834245 1974
7
Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation. 54 61
19477965 2009
8
Characterization of a novel Nav1.5 channel mutation, A551T, associated with Brugada syndrome. 61 54
19706159 2009
9
MinK-dependent internalization of the IKs potassium channel. 54 61
19202166 2009
10
Dynamic change in ST-segment and spontaneous occurrence of ventricular fibrillation in Brugada syndrome with a novel nonsense mutation in the SCN5A gene during long-term follow-up. 54 61
19075524 2009
11
Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. 61 54
18551196 2008
12
Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. 54 61
18355654 2008
13
Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction. 61 54
17675083 2007
14
A novel SCN5A mutation, F1344S, identified in a patient with Brugada syndrome and fever-induced ventricular fibrillation. 54 61
16616735 2006
15
Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. 54 61
16415376 2006
16
Short QT syndrome. 61 54
15890322 2005
17
A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. 54 61
15877619 2005
18
Comparison of the effects of metoclopramide and domperidone on HERG channels. 54 61
15640612 2005
19
Clinical and electrophysiological characteristics of Brugada syndrome caused by a missense mutation in the S5-pore site of SCN5A. 61 54
15828879 2005
20
Assessment of markers for identifying patients at risk for life-threatening arrhythmic events in Brugada syndrome. 54 61
15673386 2005
21
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. 61 54
15673388 2005
22
Two components of delayed rectifier K+ current in heart: molecular basis, functional diversity, and contribution to repolarization. 54 61
14769199 2004
23
Is timing everything? Therapeutic potential of modulators of cardiac Na(+) transporters. 54 61
12831348 2003
24
Nucleotide changes in the translated region of SCN5A from Japanese patients with Brugada syndrome and control subjects. 61 54
12639704 2003
25
SNP S1103Y in the cardiac sodium channel gene SCN5A is associated with cardiac arrhythmias and sudden death in a white family. 61 54
12471205 2002
26
Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. 61 54
12904146 2002
27
Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. 61 54
11972032 2002
28
Expression and intracellular localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada syndrome. 61 54
11786529 2002
29
Novel mechanism for Brugada syndrome: defective surface localization of an SCN5A mutant (R1432G). 61 54
11420310 2001
30
Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. 61 54
11334845 2001
31
Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children. 54 61
11781953 2001
32
HMR 1883, a cardioselective K(ATP) channel blocker, inhibits ischaemia- and reperfusion-induced ventricular fibrillation in rats. 61 54
10543431 1999
33
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. 61 54
10219239 1999
34
The eag family of K+ channels in Drosophila and mammals. 61 54
10414305 1999
35
Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. 54 61
8529801 1996
36
Usefulness of CKMB and troponin T determinations in patients with acute myocardial infarction complicated by ventricular fibrillation. 54 61
8416755 1993
37
Left-ventricular innervation assessed by 123I-SPECT/CT is associated with cardiac events in inherited arrhythmia syndromes. 61
32201099 2020
38
Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. 61
31925673 2020
39
Targeted temperature management in cardiac arrest patients with a non-shockable rhythm: A national perspective. 61
32485327 2020
40
Implantable cardioverter defibrillator for alectinib induced ventricular fibrillation. 61
31631703 2020
41
Rescue Extracorporeal Bypass to Prevent Atrioesophageal Fistula-related Air Embolism. 61
31877286 2020
42
Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis. 61
32166494 2020
43
Fabry cardiomyopathy: Gb3-induced auto-reactive panmyocarditis requiring heart transplantation. 61
32347011 2020
44
Single Coil Implantable Cardioverter Defibrillator Leads in Patients With Hypertrophic Cardiomyopathy. 61
32305220 2020
45
Risk Stratification of Patients With Apparently Idiopathic Premature Ventricular Contractions: A Multicenter International CMR Registry. 61
32553224 2020
46
The del Nido versus cold blood cardioplegia in aortic valve replacement: A randomized trial. 61
31358336 2020
47
Impact of different selection policies on subcutaneous ICD implants and therapies. 61
32385939 2020
48
Indication and prognostic significance of programmed ventricular stimulation in asymptomatic patients with Brugada syndrome. 61
32167564 2020
49
Burden of Arrhythmias in Acute Myocardial Infarction Complicated by Cardiogenic Shock. 61
32307093 2020
50
Sudden Cardiac Arrest with Shockable Rhythm in Patients with Heart Failure. 61
32504821 2020

Variations for Ventricular Fibrillation, Paroxysmal Familial, 1

ClinVar genetic disease variations for Ventricular Fibrillation, Paroxysmal Familial, 1:

6 (show top 50) (show all 244) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NKX2-5 NM_004387.4(NKX2-5):c.711C>A (p.Tyr237Ter)SNV Pathogenic 523473 rs1554093433 5:172659836-172659836 5:173232833-173232833
2 SCN5A NM_000335.5(SCN5A):c.665G>A (p.Arg222Gln)SNV Pathogenic 39444 rs45546039 3:38655272-38655272 3:38613781-38613781
3 CACNA1C NM_000719.7(CACNA1C):c.1114-316G>ASNV Pathogenic 155775 rs587782933 12:2613692-2613692 12:2504526-2504526
4 RYR2 NM_001035.3(RYR2):c.1258C>T (p.Arg420Trp)SNV Pathogenic 201214 rs190140598 1:237608788-237608788 1:237445488-237445488
5 DSP NM_004415.4(DSP):c.2528C>A (p.Ser843Ter)SNV Pathogenic 374137 rs1057518920 6:7575619-7575619 6:7575386-7575386
6 SCN5A NM_198056.2(SCN5A):c.1099C>T (p.Arg367Cys)SNV Pathogenic/Likely pathogenic 67633 rs199473097 3:38648201-38648201 3:38606710-38606710
7 SCN5A NM_198056.2(SCN5A):c.5129C>T (p.Ser1710Leu)SNV Pathogenic/Likely pathogenic 9383 rs137854604 3:38592734-38592734 3:38551243-38551243
8 SCN5A NM_000335.5(SCN5A):c.3305C>A (p.Ser1102Tyr)SNV risk factor 9393 rs7626962 3:38620907-38620907 3:38579416-38579416
9 SCN5A NM_000335.5(SCN5A):c.*1414G>CSNV Conflicting interpretations of pathogenicity 902458 3:38590398-38590398 3:38548907-38548907
10 RYR2 NM_001035.3(RYR2):c.2267G>A (p.Ser756Asn)SNV Conflicting interpretations of pathogenicity 36739 rs193922623 1:237664074-237664074 1:237500774-237500774
11 SCN5A NM_000335.5(SCN5A):c.2436+12G>ASNV Conflicting interpretations of pathogenicity 36758 rs41312419 3:38628879-38628879 3:38587388-38587388
12 SCN5A NM_000335.5(SCN5A):c.4215G>A (p.Gly1405=)SNV Conflicting interpretations of pathogenicity 36761 rs41311123 3:38601665-38601665 3:38560174-38560174
13 SCN5A NM_000335.5(SCN5A):c.4434+13C>TSNV Conflicting interpretations of pathogenicity 36762 rs148598985 3:38597919-38597919 3:38556428-38556428
14 SCN5A NM_000335.5(SCN5A):c.4506C>T (p.Ser1502=)SNV Conflicting interpretations of pathogenicity 36763 rs45548237 3:38597180-38597180 3:38555689-38555689
15 SCN5A NM_000335.5(SCN5A):c.3993G>A (p.Pro1331=)SNV Conflicting interpretations of pathogenicity 901564 3:38601887-38601887 3:38560396-38560396
16 SCN5A NM_198056.2(SCN5A):c.4170C>T (p.Thr1390=)SNV Conflicting interpretations of pathogenicity 518780 rs747356664 3:38601713-38601713 3:38560222-38560222
17 SCN5A NM_198056.2(SCN5A):c.5938G>T (p.Val1980Phe)SNV Conflicting interpretations of pathogenicity 520462 rs772258197 3:38591925-38591925 3:38550434-38550434
18 SCN5A NM_198056.2(SCN5A):c.934+4C>TSNV Conflicting interpretations of pathogenicity 463361 rs182050752 3:38651221-38651221 3:38609730-38609730
19 SCN5A NM_198056.2(SCN5A):c.4296G>A (p.Arg1432=)SNV Conflicting interpretations of pathogenicity 463336 rs199473246 3:38598725-38598725 3:38557234-38557234
20 SCN5A NM_198056.2(SCN5A):c.4917G>A (p.Gly1639=)SNV Conflicting interpretations of pathogenicity 516646 rs1419998623 3:38592946-38592946 3:38551455-38551455
21 SCN5A NM_198056.2(SCN5A):c.5795C>T (p.Ala1932Val)SNV Conflicting interpretations of pathogenicity 582721 rs371194826 3:38592068-38592068 3:38550577-38550577
22 SCN5A NM_000335.5(SCN5A):c.5847C>T (p.Tyr1949=)SNV Conflicting interpretations of pathogenicity 704320 3:38592013-38592013 3:38550522-38550522
23 SCN5A NM_198056.2(SCN5A):c.3798C>T (p.Tyr1266=)SNV Conflicting interpretations of pathogenicity 629343 rs371610895 3:38607942-38607942 3:38566451-38566451
24 SCN5A NM_000335.5(SCN5A):c.*1820C>GSNV Conflicting interpretations of pathogenicity 900711 3:38589992-38589992 3:38548501-38548501
25 SCN5A NM_000335.5(SCN5A):c.1681C>T (p.Leu561=)SNV Conflicting interpretations of pathogenicity 48290 rs45522138 3:38645412-38645412 3:38603921-38603921
26 SCN5A NM_000335.5(SCN5A):c.5882C>T (p.Pro1961Leu)SNV Conflicting interpretations of pathogenicity 48313 rs199473638 3:38591978-38591978 3:38550487-38550487
27 SCN5A NM_000335.5(SCN5A):c.6007T>C (p.Phe2003Leu)SNV Conflicting interpretations of pathogenicity 48315 rs41311117 3:38591853-38591853 3:38550362-38550362
28 SCN5A NM_000335.5(SCN5A):c.717C>T (p.Ile239=)SNV Conflicting interpretations of pathogenicity 48316 rs41285129 3:38651442-38651442 3:38609951-38609951
29 KCNQ1 NM_000218.2(KCNQ1):c.160_168dup (p.Ile54_Pro56dup)duplication Conflicting interpretations of pathogenicity 42487 rs397515877 11:2466480-2466481 11:2445250-2445251
30 SCN5A NM_000335.5(SCN5A):c.630G>A (p.Val210=)SNV Conflicting interpretations of pathogenicity 36766 rs193922727 3:38655307-38655307 3:38613816-38613816
31 SCN5A NM_000335.5(SCN5A):c.647C>T (p.Ser216Leu)SNV Conflicting interpretations of pathogenicity 36767 rs41276525 3:38655290-38655290 3:38613799-38613799
32 TPM1 NM_001018005.2(TPM1):c.240+4430G>ASNV Conflicting interpretations of pathogenicity 43683 rs397516490 15:63340781-63340781 15:63048582-63048582
33 RBM20 NM_001134363.3(RBM20):c.2565_2570del (p.Gln856_Glu857del)deletion Conflicting interpretations of pathogenicity 43992 rs397516603 10:112579840-112579845 10:110820082-110820087
34 TTN NM_001267550.2(TTN):c.33501_33503AGA[6] (p.Glu11172dup)short repeat Conflicting interpretations of pathogenicity 46889 rs368327166 2:179544685-179544686 2:178679958-178679959
35 TTN NM_001267550.2(TTN):c.58636G>C (p.Glu19546Gln)SNV Conflicting interpretations of pathogenicity 47137 rs201840554 2:179458391-179458391 2:178593664-178593664
36 TTN NM_001267550.2(TTN):c.95653G>A (p.Ala31885Thr)SNV Conflicting interpretations of pathogenicity 47561 rs72648263 2:179410184-179410184 2:178545457-178545457
37 KCNE3 , LIPT2 NM_005472.4(KCNE3):c.248G>A (p.Arg83His)SNV Conflicting interpretations of pathogenicity 5541 rs17215437 11:74168361-74168361 11:74457316-74457316
38 SCN5A NM_000335.5(SCN5A):c.1441C>T (p.Arg481Trp)SNV Conflicting interpretations of pathogenicity 48284 rs144511230 3:38646297-38646297 3:38604806-38604806
39 SCN5A NM_000335.5(SCN5A):c.2074C>A (p.Gln692Lys)SNV Conflicting interpretations of pathogenicity 67712 rs45553235 3:38639408-38639408 3:38597917-38597917
40 SCN5A NM_000335.5(SCN5A):c.2944T>C (p.Cys982Arg)SNV Conflicting interpretations of pathogenicity 67769 rs199473182 3:38622706-38622706 3:38581215-38581215
41 SCN5A NM_198056.2(SCN5A):c.2957G>A (p.Arg986Gln)SNV Conflicting interpretations of pathogenicity 67770 rs41313667 3:38622693-38622693 3:38581202-38581202
42 SCN5A NM_000335.5(SCN5A):c.1336G>A (p.Glu446Lys)SNV Conflicting interpretations of pathogenicity 67656 rs199473339 3:38647444-38647444 3:38605953-38605953
43 SCN5A NM_198056.2(SCN5A):c.1567C>T (p.Arg523Cys)SNV Conflicting interpretations of pathogenicity 67667 rs199473119 3:38645526-38645526 3:38604035-38604035
44 SCN5A NM_000335.5(SCN5A):c.3010T>C (p.Cys1004Arg)SNV Conflicting interpretations of pathogenicity 67772 rs199473183 3:38622640-38622640 3:38581149-38581149
45 SCN5A NM_000335.5(SCN5A):c.3724G>A (p.Asp1242Asn)SNV Conflicting interpretations of pathogenicity 67820 rs199473599 3:38608013-38608013 3:38566522-38566522
46 SCN5A NM_198056.2(SCN5A):c.4057G>A (p.Val1353Met)SNV Conflicting interpretations of pathogenicity 67857 rs199473233 3:38601826-38601826 3:38560335-38560335
47 SCN5A NM_000335.5(SCN5A):c.52C>T (p.Arg18Trp)SNV Conflicting interpretations of pathogenicity 67978 rs199473044 3:38674747-38674747 3:38633256-38633256
48 SCN5A NM_000335.4(SCN5A):c.5333C>T (p.Thr1778Met)SNV Conflicting interpretations of pathogenicity 67985 rs199473634 3:38592527-38592527 3:38551036-38551036
49 SCN5A NM_000335.5(SCN5A):c.5357G>A (p.Ser1786Asn)SNV Conflicting interpretations of pathogenicity 67988 rs199473316 3:38592503-38592503 3:38551012-38551012
50 SCN5A NM_198056.2(SCN5A):c.3292G>T (p.Val1098Leu)SNV Conflicting interpretations of pathogenicity 67788 rs199473191 3:38620923-38620923 3:38579432-38579432

UniProtKB/Swiss-Prot genetic disease variations for Ventricular Fibrillation, Paroxysmal Familial, 1:

73
# Symbol AA change Variation ID SNP ID
1 SCN5A p.Ser1710Leu VAR_017685 rs137854604

Expression for Ventricular Fibrillation, Paroxysmal Familial, 1

Search GEO for disease gene expression data for Ventricular Fibrillation, Paroxysmal Familial, 1.

Pathways for Ventricular Fibrillation, Paroxysmal Familial, 1

Pathways related to Ventricular Fibrillation, Paroxysmal Familial, 1 according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.8 TNNT2 SLC9A1 RYR2 NGF CACNA1C
2
Show member pathways
12.54 TNNT2 SCN5A RYR2 NKX2-5 KCNQ1 KCNH2
3
Show member pathways
12.52 RYR2 KCNQ1 KCNJ5 CACNA1C
4 12.16 KCNQ1 KCNJ5 KCNH2 KCNE2 KCNE1 CACNA1C
5
Show member pathways
12.06 TNNT2 SLC9A1 SCN5A RYR2 KNG1 KCNQ1
6 11.98 SCN5A RYR2 NGF KCNQ1 KCNH2
7
Show member pathways
11.94 SLC9A1 KCNQ1 KCNE2
8
Show member pathways
11.88 RYR2 DSP CACNA1C
9
Show member pathways
11.86 KCNQ1 KCNJ5 KCNH2
10 11.64 SLC9A1 RYR2 KCNQ1
11 11.64 TNNT2 SLC9A1 RYR2 CACNA1C
12
Show member pathways
11.53 SCN5A KCNQ1 KCNE2 KCNE1 CACNA1C
13 11.33 TNNT2 SCN5A NKX2-5
14 11.02 SCN5A RYR2 KCNQ1 KCNJ5 KCNH2 KCNE2
15 10.76 KCNQ1 KCNE1

GO Terms for Ventricular Fibrillation, Paroxysmal Familial, 1

Cellular components related to Ventricular Fibrillation, Paroxysmal Familial, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.11 SLC9A1 SCN5A RYR2 KNG1 KCNQ1 KCNJ5
2 cell surface GO:0009986 9.8 SLC9A1 SCN5A KCNH2 KCNE2 KCNE1
3 Z disc GO:0030018 9.56 SCN5A RYR2 KCNE1 CACNA1C
4 intercalated disc GO:0014704 9.5 SLC9A1 SCN5A DSP
5 sarcolemma GO:0042383 9.46 SLC9A1 SCN5A RYR2 CACNA1C
6 T-tubule GO:0030315 9.26 SLC9A1 SCN5A KCNJ5 CACNA1C
7 voltage-gated potassium channel complex GO:0008076 9.02 KCNQ1 KCNJ5 KCNH2 KCNE2 KCNE1

Biological processes related to Ventricular Fibrillation, Paroxysmal Familial, 1 according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.11 SLC9A1 SCN5A RYR2 KCNQ1 KCNJ5 KCNH2
2 transmembrane transport GO:0055085 10.08 SLC9A1 SCN5A RYR2 KCNQ1 KCNH2 CACNA1C
3 regulation of ion transmembrane transport GO:0034765 9.95 SCN5A KCNQ1 KCNJ5 KCNH2 KCNE2 KCNE1
4 potassium ion transport GO:0006813 9.93 KCNQ1 KCNJ5 KCNH2 KCNE2 KCNE1
5 potassium ion transmembrane transport GO:0071805 9.92 SLC9A1 KCNQ1 KCNH2 KCNE2 KCNE1
6 cellular response to drug GO:0035690 9.82 KCNQ1 KCNH2 KCNE2
7 cardiac muscle cell action potential involved in contraction GO:0086002 9.81 SCN5A KCNE2 KCNE1 CACNA1C
8 potassium ion export across plasma membrane GO:0097623 9.8 KCNQ1 KCNH2 KCNE2 KCNE1
9 cardiac conduction GO:0061337 9.8 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 CACNA1C
10 potassium ion import across plasma membrane GO:1990573 9.79 KCNJ5 KCNH2 KCNE2
11 membrane repolarization GO:0086009 9.78 KCNQ1 KCNH2 KCNE2 KCNE1
12 regulation of potassium ion transmembrane transport GO:1901379 9.77 KCNH2 KCNE2 KCNE1
13 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.77 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
14 positive regulation of potassium ion transmembrane transport GO:1901381 9.76 KCNQ1 KCNH2 KCNE1
15 cellular response to epinephrine stimulus GO:0071872 9.75 SLC9A1 RYR2 KCNQ1
16 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.74 RYR2 DSP CACNA1C
17 regulation of membrane repolarization GO:0060306 9.73 KCNQ1 KCNH2 KCNE2
18 membrane repolarization during action potential GO:0086011 9.73 KCNQ1 KCNH2 KCNE2 KCNE1
19 cardiac muscle contraction GO:0060048 9.73 TNNT2 SCN5A RYR2 NKX2-5 KCNQ1 KCNH2
20 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.72 KCNQ1 KCNH2 KCNE1
21 cardiac muscle cell differentiation GO:0055007 9.69 SLC9A1 NKX2-5
22 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.69 RYR2 CACNA1C
23 positive regulation of heart rate GO:0010460 9.69 RYR2 KCNQ1
24 regulation of cardiac muscle contraction GO:0055117 9.68 RYR2 NKX2-5
25 membrane depolarization during action potential GO:0086010 9.68 SCN5A KCNH2
26 cardiovascular system development GO:0072358 9.68 NKX2-5 KCNQ1
27 response to muscle stretch GO:0035994 9.68 SLC9A1 RYR2
28 positive regulation of sodium ion transport GO:0010765 9.67 SCN5A NKX2-5
29 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.67 KCNE2 KCNE1
30 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.67 RYR2 CACNA1C
31 calcium ion transport into cytosol GO:0060402 9.66 RYR2 CACNA1C
32 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.66 SCN5A CACNA1C
33 atrial cardiac muscle cell action potential GO:0086014 9.65 SCN5A KCNQ1
34 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.65 SLC9A1 RYR2
35 regulation of delayed rectifier potassium channel activity GO:1902259 9.64 KCNE2 KCNE1
36 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.64 SCN5A KCNQ1
37 membrane repolarization during atrial cardiac muscle cell action potential GO:0098914 9.63 KCNQ1 KCNJ5
38 positive regulation of the force of heart contraction GO:0098735 9.63 SLC9A1 RYR2
39 membrane depolarization during AV node cell action potential GO:0086045 9.62 SCN5A CACNA1C
40 positive regulation of action potential GO:0045760 9.62 SLC9A1 SCN5A
41 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.61 SCN5A CACNA1C
42 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.55 KCNQ1 KCNJ5 KCNH2 KCNE2 KCNE1
43 ventricular cardiac muscle cell action potential GO:0086005 9.43 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 KCNE1
44 regulation of heart rate by cardiac conduction GO:0086091 9.23 SCN5A KCNQ1 KCNJ5 KCNH2 KCNE2 KCNE1

Molecular functions related to Ventricular Fibrillation, Paroxysmal Familial, 1 according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.38 TNNT2 SLC9A1 SCN5A RYR2 NKX2-5 NGF
2 calmodulin binding GO:0005516 9.85 SLC9A1 SCN5A RYR2 KCNQ1 CACNA1C
3 ion channel activity GO:0005216 9.83 SCN5A RYR2 KCNQ1 KCNH2 CACNA1C
4 potassium channel activity GO:0005267 9.78 KCNQ1 KCNH2 KCNE2 KCNE1
5 ion channel binding GO:0044325 9.72 SCN5A RYR2 KCNQ1 KCNE2 KCNE1
6 voltage-gated potassium channel activity GO:0005249 9.71 KCNQ1 KCNH2 KCNE2 KCNE1
7 inward rectifier potassium channel activity GO:0005242 9.67 KCNJ5 KCNH2 KCNE2
8 scaffold protein binding GO:0097110 9.67 SCN5A KCNQ1 KCNH2 DSP
9 protein kinase A regulatory subunit binding GO:0034237 9.55 RYR2 KCNQ1
10 protein kinase A catalytic subunit binding GO:0034236 9.52 RYR2 KCNQ1
11 voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization GO:0086089 9.51 KCNQ1 KCNJ5
12 voltage-gated ion channel activity GO:0005244 9.5 SCN5A KCNQ1 KCNJ5 KCNH2 KCNE2 KCNE1
13 delayed rectifier potassium channel activity GO:0005251 9.46 KCNQ1 KCNH2 KCNE2 KCNE1
14 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.43 KCNQ1 KCNH2 KCNE1
15 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.02 KCNQ1 KCNJ5 KCNH2 KCNE2 KCNE1

Sources for Ventricular Fibrillation, Paroxysmal Familial, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....